Free Trial

agilon health (AGL) Stock Forecast & Price Target

agilon health logo
$4.43 -0.05 (-1.12%)
As of 10:41 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

agilon health - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
2
Hold
13
Buy
2

Based on 17 Wall Street analysts who have issued ratings for agilon health in the last 12 months, the stock has a consensus rating of "Hold." Out of the 17 analysts, 2 have given a sell rating, 13 have given a hold rating, and 2 have given a buy rating for AGL.

Consensus Price Target

$3.95
-10.75% Downside
According to the 17 analysts' twelve-month price targets for agilon health, the average price target is $3.95. The highest price target for AGL is $9.00, while the lowest price target for AGL is $2.00. The average price target represents a forecasted downside of -10.75% from the current price of $4.43.
Get the Latest News and Ratings for AGL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for agilon health and its competitors.

Sign Up

AGL Analyst Ratings Over Time

TypeCurrent Forecast
3/25/24 to 3/25/25
1 Month Ago
2/24/24 to 2/23/25
3 Months Ago
12/26/23 to 12/25/24
1 Year Ago
3/26/23 to 3/25/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
4 Buy rating(s)
Hold
13 Hold rating(s)
14 Hold rating(s)
16 Hold rating(s)
11 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
3 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$3.95$4.03$4.28$9.73
Forecasted Upside-10.75% Downside14.29% Upside124.26% Upside104.21% Upside
Consensus Rating
Hold
Hold
Reduce
Hold
Remove Ads

AGL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AGL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

agilon health Stock vs. The Competition

Typeagilon healthMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.82
2.54
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside-11.45% Downside21,103.94% Upside16.92% Upside
News Sentiment Rating
Positive News

See Recent AGL News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/21/2025Needham & Company LLC
2 of 5 stars
M. Shea
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
2/26/2025Royal Bank of Canada
4 of 5 stars
Sean Dodge
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$3.00 ➝ $3.50-3.61%
2/26/2025Stifel Nicolaus
4 of 5 stars
Craig Jones
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetHold ➝ Hold$2.00 ➝ $3.00-19.03%
1/15/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Wilkes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetMarket Perform ➝ Market Perform$2.50 ➝ $3.15+14.13%
1/10/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Grosslight
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Neutral$1.75 ➝ $2.25+1.81%
12/16/2024Macquarie
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Qiu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$3.00+33.93%
11/11/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$6.00 ➝ $2.00-1.96%
11/11/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$5.00 ➝ $2.00+7.53%
11/11/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Davides
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
11/8/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Daniels
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
10/8/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetIn-Line ➝ In-Line$7.00 ➝ $4.00+25.79%
10/2/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Underperform$3.00-14.53%
8/9/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$5.00 ➝ $4.00-27.67%
8/8/2024Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00+57.89%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/30/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$6.00+4.08%
5/24/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$6.40 ➝ $6.50+15.15%
2/26/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$25.00 ➝ $6.50+3.67%
1/8/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
W. Mayo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
1/8/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
1/8/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Peer Perform
1/5/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$17.00 ➝ $9.00+12.36%
12/11/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$14.00+21.21%
11/13/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$23.00 ➝ $16.00+47.47%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:41 AM ET.


AGL Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for agilon health is $3.95, with a high forecast of $9.00 and a low forecast of $2.00.

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for agilon health in the last twelve months. There are currently 2 sell ratings, 13 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AGL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGL, but not buy additional shares or sell existing shares.

According to analysts, agilon health's stock has a predicted downside of -10.75% based on their 12-month stock forecasts.

Over the previous 90 days, agilon health's stock had 1 upgrade by analysts.

agilon health has been rated by research analysts at Citigroup, Needham & Company LLC, Royal Bank of Canada, Sanford C. Bernstein, and Stifel Nicolaus in the past 90 days.

Analysts like agilon health less than other "medical" companies. The consensus rating for agilon health is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AGL compares to other companies.


This page (NYSE:AGL) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners